8-K: Neuronetics Announces CFO Appointment and Management Changes

Neuronetics appoints Nir Naor as CFO, promotes Cory Anderson, and announces Andrew Macan's departure.

Summary

• Neuronetics, Inc. announced significant management changes, including the appointment of Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer, effective July 23, 2026.
• W. Andrew Macan, Executive Vice President, Chief Legal Officer, and Corporate Secretary, will depart on August 15, 2026, after entering into a Separation Agreement.
• Cory Anderson has been promoted to Executive Vice President and General Manager of Greenbrook, effective July 1, 2026.
• Nir Naor brings over 20 years of finance and life sciences experience, most recently serving as CFO of Axogen, Inc., where he contributed to the company achieving profitability and tripling its market capitalization.
• Mr. Naor's compensation package includes an annual base salary of $480,000, eligibility for a discretionary annual cash bonus targeted at 50% of his base salary, and a grant of 500,000 Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive announcement, driven by the strategic appointment of an experienced CFO with a proven track record, balanced by the departure of a key executive.

Positives

• Appointment of Nir Naor as CFO, who has a strong track record of financial discipline and driving profitability, as demonstrated at Axogen.
• Nir Naor's experience includes helping Axogen achieve profitability and cash flow positivity within one year, contributing to a tripling of its market capitalization.
• Cory Anderson's promotion to lead the Greenbrook business reflects its growth and his expanded leadership responsibilities.
• Nir Naor's compensation includes a significant RSU grant (500,000 units) vesting over four years, aligning his interests with long-term shareholder value.
• The company highlights Nir Naor's eagerness to strengthen the balance sheet, drive operating leverage, and improve margins and shareholder returns.

Negatives

• Departure of W. Andrew Macan, who has served in key legal and corporate secretary roles since January 2020.
• Mr. Macan will receive a separation payment of $475,087.50, in addition to a retention bonus and vested RSUs, representing a notable cash outflow.

Risks

• The company's ability to execute its business strategy and achieve or sustain profitable operations due to its history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System for revenue generation.
• Availability of coverage and reimbursement from third-party payors for treatments using their products.
• Competition from other technologies and therapies for the indications treated by their products.
• Potential effects of evolving and/or extensive government regulation in the U.S. and other jurisdictions.

Future Outlook

The company aims to strengthen its balance sheet, drive greater operating leverage, and convert business momentum into durable margins and attractive returns for shareholders, as stated by the new CFO, Nir Naor.

Management Comments

• "Nir is a proven leader who brings the financial discipline and rigor our strategy demands. Across medical device and care-delivery models, he has consistently delivered profitable revenue growth and healthy cash flow while building high-performing teams and sharpening capital allocation. He is the ideal person to help us execute our strategy, expand access to our therapies, and improve the lives of the patients we serve."
• "Neuronetics stands at the forefront of neurohealth and operates a national network of clinics with significant potential. The opportunity ahead is meaningful, and I am eager to work alongside Dan and the organization to strengthen the companys balance sheet, drive greater operating leverage, and convert the businesss momentum into durable margins and attractive returns for shareholders. I look forward to helping unlock the full value of this platform."
• "Corys deep knowledge of interventional psychiatry and focus on operational excellence make him the ideal leader to continue advancing our clinic strategy and expanding access to patient care."
• "Andy has been an integral part of the Neuronetics journey for many years. I have appreciated his help as I assumed leadership of the company and wish him well in his next endeavor."

Industry Context

StockSavvy.ai notes that Neuronetics' focus on interventional mental health and its combination of TMS technology with a clinic network positions it within a growing sector addressing unmet needs in mental healthcare. The appointment of a CFO with a strong background in life sciences and a history of driving profitability at companies like Axogen suggests a strategic emphasis on financial discipline and growth acceleration.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact from the appointment of an experienced CFO focused on financial discipline and shareholder returns; potential negative impact from severance costs for the departing executive.
• Employees: Potential impact from management changes and the strategic direction set by new leadership.
• Patients: Continued focus on expanding access to interventional mental health therapies through the NeuroStar TMS and Greenbrook clinic network.

Next Steps

• Nir Naor to assume CFO responsibilities on July 23, 2026.
• W. Andrew Macan's departure effective August 15, 2026.
• Continued execution of the company's strategy to expand access to therapies and improve patient lives.

Key Dates

Recommendation

The filing announces routine management changes, including the appointment of a new CFO with a strong background and the departure of a legal officer. While the new CFO's experience is positive, there are no significant financial results or strategic shifts detailed that would warrant a strong buy or sell recommendation at this time. The company's ongoing challenges with profitability and reliance on its core technology remain key considerations.

Keywords

Neuronetics, CFO Appointment, Nir Naor, Management Changes, Axogen, NeuroStar TMS, Greenbrook, Corporate Secretary